Centessa Pharmaceuticals : Guggenheim Nantucket Therapeutics Conference Presentation

Guggenheim Nantucket Therapeutics Conference

Asset-Centric.Patient-Centric.

Disclaimer

This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor's particular objectives, financial situation or needs. The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements, including, without limitation, statements related to the Company's ability to deliver impactful medicines to patients; the ability of our key executives to drive execution of the Company's portfolio of programs; our asset-centric business model and the intended advantages and benefits thereof; research and clinical development plans; the scope, progress, results and costs of developing our product candidates or any other future product candidates; the development and therapeutic potential of our product candidates, including SerpinPC, LB101, MGX292, OX2R and our LockBody platform; strategy; regulatory matters, including the timing and likelihood of success of obtaining approvals to initiate or continue clinical trials or market any products; market size and opportunity for our product candidates; and our anticipated cash runway. Words such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," "aim," "seek," and variations of these words or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including, without limitation, risks related to our ability to protect and maintain our intellectual property position; business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing products and

technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; future expenditures risks related to our asset-centric corporate model; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and risks related to the COVID-19 pandemic including the effects of the Delta, Omicron and any other variants, geo-political risks such as the Russia-Ukraine conflict and other risk factors contained in our filings with the U.S. Securities and Exchange Commission. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. All projections, valuations and statistical analyses are provided for information purposes only. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory agency. No representation or warranty, express or implied, is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation or warranty, express or implied, as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Discovering and developing medicines that are truly transformational for patients

Multiple potential blockbuster assets with clinical readouts anticipated over next two years

Cash runway into 2026 enables clinical proof of concept readouts across portfolio

World-class R&D team

Note: $484.2 million in cash and cash equivalents as of June 30, 2022.

3

DIFFERENTIATION

We are a transformational pharmaceutical company fueling an innovative pipeline

Focused development

teams

Minimal		Innovative
infrastructure	Asset-Centric.	and
and	Patient-Centric.	uncorrelated
fixed costs		assets

Data-driven 'go / no-go' decisions

MULTIPLE PATHWAYS TO

SIGNIFICANT VALUE CREATION

	Lead Assets	Disease	Estimated
	Market Size*
	SerpinPC	Hemophilia B	$2B+1
	LB101	Solid Tumors	$10B1
	MGX292	Pulmonary Arterial	$6B1
	Hypertension (PAH)
	OX2R Agonists	Narcolepsy (NT1)	$2B+1

*Source: 1Evaluate Pharma 2021 and 2internal estimates	4
Centessa has several earlier stage programs that are not reflected on this slide.

POTENTIAL FIRST-IN-CLASS/BEST-IN-CLASS MEDICINES FOR PATIENTS
Rare disease and immuno-oncology pipeline	LEGEND	Expected Milestone
	Timing

PRE-CLINICAL	PHASE 1	PHASE 2	REGISTRATIONAL
SerpinPC in Hemophilia (Hemophilia B Registrational Trial)			2H22 Registrational Trial Initiation
		4Q22 Data from Ph 2a OLE Study
LB101 in Solid Tumors	4Q22 IND Submission

MGX292 in Pulmonary Arterial Hypertension (PAH)

OX2R Agonists in Narcolepsy (NT1)

CBS001 in Inflammatory/ Fibrotic Diseases

CBS004 in Systemic Sclerosis, Lupus Erythematosus

CASH RUNWAY INTO 2026 ENABLES CLINICAL PROOF OF CONCEPT READOUTS ACROSS PIPELINE

$484.2 million in cash and cash equivalents as of June 30, 2022.

Notes: OLE is open label extension.
Additional LockBody® molecules, such as LB201 are being progressed toward candidate selection expected early 2023.	5
Centessa has several earlier stage programs that are not reflected on this slide.